Becton Dickinson (BDX) and Quest Diagnostics (DGX) announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BD Board Declares Dividend
- BD experiencing reduced availability of BD BACTEC vials from supplier
- Becton Dickinson price target lowered to $255 from $260 at Citi
- Becton Dickinson added to ‘Tactical Outperform’ list, target trimmed at Evercore
- 3 Best Healthcare Stocks to Buy in June 2024, as per Analysts